trastuzumab deruxtecan SC (T DXd SC) / Daiichi Sankyo, Alteogen - LARVOL DELTA

Daiichi Sankyo’s Enhertu SC (trastuzumab deruxtecan), also powered by Alteogen’s technology, is slated to enter phase 1 trials in September in the U.S. (Korea Biomedical Review) - "Eligibility includes adults with HER2-positive or HER2-low breast cancer who have received prior anti-HER2 therapy or chemotherapy, while patients with prior exatecan-based antibody-drug conjugate (ADC) treatment or certain cardiac and pulmonary conditions are excluded."

Trial status • Solid Tumor